首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1692592

VISTA抑制剂的全球市场:临床试验，医药品开发机会，专利的洞察(2025年)

Global VISTA Inhibitor Clinical Trials, Drug Development Opportunities & Patent Insight 2025

出版日期: 2025年04月01日 | 出版商:

KuicK Research | 英文 75 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

近年来，癌症免疫治疗领域发生了显着变化，免疫检查点抑制剂彻底改变了各种恶性肿瘤的治疗方法。随着第一代免疫检查点抑制剂（如派姆单抗和纳武单抗）的巨大成功，研究人员目前正致力于识别新的免疫检查点蛋白。 T 细胞活化的 V 结构域免疫球蛋白抑制剂 (VISTA) 已成为此创新领域的下一代目标。

VISTA 是一种关键的免疫检查点蛋白，在控制免疫反应中起着微妙的作用，尤其是在肿瘤微环境中。与 PD-1 和 CTLA-4 等研究更广泛的检查点分子不同，VISTA 是一个相对较新的靶点，具有尚未开发的潜力。越来越多的研究认识到 VISTA 在调节 T 细胞活化和抑制抗肿瘤免疫反应中的重要性，这使得 VISTA 成为标靶免疫治疗策略的有趣候选人。

目前的免疫疗法前景与现有免疫检查点抑制剂的显着成功相似，这表明针对 VISTA 的疗法具有巨大的前景。 PD-1 和 CTLA-4 抑制剂的突破为更复杂、更精确的免疫调节干预铺平了道路。这些先例为探索 VISTA 等新型检查点标靶提供了强有力的科学验证和投资者信心，预示着变革性治疗方法的潜力。

VISTA 标靶治疗中最有前景的进展之一是 CA-170，这是由 Aurigene Oncology 和 Curis 开发的创新口服小分子。该化合物是一种优雅的双重抑制剂，同时针对 VISTA 和 PD-L1，与传统的基于抗体的方法相比具有多种吸引人的优势。这种分子可以口服，有可能减少併发症并使免疫相关不良事件更易于控制，这使其有别于传统的免疫治疗策略。

Aurigene Oncology 和 Curis 之间的策略合作凸显了人们对 VISTA 标靶疗法的极大兴趣和商业潜力。透过在不同地区划分开发权，此次合作凸显了全球科学界对 VISTA 治疗潜力的认可。正在进行的后期临床试验，特别是研究 CA-170 对非小细胞肺癌疗效的 2b/3 期研究，代表着了解该分子临床效用的重要里程碑。

临床前和早期研究揭示了 VISTA 复杂的免疫调节机制。与几种检查点蛋白不同，VISTA 表现出抑制 T 细胞反应的独特特性，这对癌症免疫疗法具有微妙的意义。初步研究表明，抑制 VISTA 有可能重振抗肿瘤免疫反应，为现有的检查点阻断策略提供补充或替代方法。

缺乏经批准的 VISTA 标靶疗法对研究人员和药物开发人员来说既是课题也是机会。该治疗领域的未知领域允许采用创新方法并允许创造性地探索 VISTA 的潜在机制。研究人员对 VISTA 克服其他检查点抑制剂所观察到的抗药性机制的潜力特别感兴趣，这可能为患有难治性恶性肿瘤的患者带来新的希望。

随着科学界不断揭示 VISTA 在免疫调节中的复杂作用，预计未来几年研究和临床开发将会加速。开发能够更精确地调节免疫反应的标靶疗法的可能性代表了个人化医疗的重大进步。儘管课题依然存在，但基础研究和正在进行的临床研究为 VISTA 标靶治疗策略描绘了乐观的前景。

本报告提供全球VISTA抑制剂市场相关调查，提供市场概要，以及药物趋势，临床试验趋势，各地区趋势，及加入此市场的主要企业竞争情形等资讯。

First VISTA Inhibitor Drug Approval By 2028
US Dominating Global VISTA Inhibitor Clinical Trials Landscape
Insight On Ongoing Clinical Trials By Company, Country, Indication & Phase
Key Drugs Clinical Study Initiation & Completion Year Overview
Global & Regional Market Development Insight By Indication
Global VISTA Inhibitors Market Dynamics & Competitive Landscape

The landscape of cancer immunotherapy has witnessed remarkable transformations in recent years, with immune checkpoint inhibitors revolutionizing treatment approaches for various malignancies. With the massive success of first generation immune checkpoint inhibitors, such as pembrolizumab and Nivolumab, researchers have now focused their efforts in identifying newer immune checkpoint proteins. Among the emerging next-generation targets in this innovative field is the V-domain immunoglobulin suppressor of T cell activation (VISTA), which represents a promising yet under-explored avenue for potential therapeutic interventions across a range of indications.

VISTA, a critical immune checkpoint protein, plays a nuanced role in regulating immune responses, particularly within the tumor microenvironment. Unlike more extensively studied checkpoint molecules like PD-1 and CTLA-4, VISTA remains a relatively nascent target with significant untapped potential. Researchers have increasingly recognized its importance in modulating T cell activation and suppressing anti-tumor immune responses, making it an intriguing candidate for targeted immunotherapeutic strategies.

The current immunotherapy landscape demonstrates considerable promise for VISTA targeted approaches, drawing parallels with the remarkable success of existing immune checkpoint inhibitors. The groundbreaking achievements of PD-1 and CTLA-4 inhibitors have paved the way for more sophisticated and precise immunomodulatory interventions. These precedents provide robust scientific validation and investor confidence in exploring novel checkpoint targets like VISTA, suggesting a potentially transformative therapeutic approach.

Among the most promising developments in VISTA targeted therapy is CA-170, an innovative oral small molecule developed by Aurigene Oncology and Curis. This compound represents a sophisticated dual inhibitor targeting both VISTA and PD-L1, offering several compelling advantages over traditional antibody-based approaches. The molecule's oral administration format, reduced complexity, and potential for more manageable immune-related adverse events distinguish it from conventional immunotherapeutic strategies.

The strategic collaboration between Aurigene and Curis highlights the significant interest and potential commercial viability of VISTA targeted therapies. By dividing development rights across different geographical regions, the partnership underscores the global scientific community's recognition of VISTA's therapeutic potential. The ongoing late-phase clinical trials, particularly the phase 2b/3 studies investigating CA-170's efficacy in non-small cell lung cancer, represent a critical milestone in understanding the molecule's clinical utility.

Preclinical and early stage research has unveiled VISTA's complex immunomodulatory mechanisms. Unlike some checkpoint proteins, VISTA exhibits unique characteristics in suppressing T cell responses, suggesting nuanced implications for cancer immunotherapy. Preliminary studies indicate that VISTA's inhibition could potentially reinvigorate anti-tumor immune responses, offering a complementary or alternative approach to existing checkpoint blockade strategies.

The lack of approved VISTA-targeted therapies presents both a challenge and an opportunity for researchers and pharmaceutical developers. The uncharted nature of this therapeutic domain invites innovative approaches and allows for creative exploration of VISTA's potential mechanisms. Researchers are particularly intrigued by VISTA's potential in overcoming resistance mechanisms observed with other checkpoint inhibitors, potentially offering new hope for patients with treatment-resistant malignancies.

Scientific interest in VISTA extends beyond oncology, with emerging research suggesting potential applications in autoimmune disorders and inflammatory conditions. This broader therapeutic landscape further amplifies the molecule's significance and underscores the importance of continued investigative efforts. The multifaceted nature of VISTA's immunomodulatory functions presents a complex yet exciting frontier for translational research.

As the scientific community continues to unravel VISTA's intricate roles in immune regulation, the coming years are likely to witness accelerated research and clinical development. The potential for developing targeted therapies that can modulate immune responses with greater precision represents a significant advancement in personalized medicine. While challenges remain, the foundational research and ongoing clinical investigations paint an optimistic picture for VISTA-targeted therapeutic strategies.

1. VISTA As Emerging Immune Checkpoint

1.1 What Is VISTA Inhibition?
1.2 Structure & Biology Of VISTA Protein
1.3 Mechanism Of Action Of VISTA Inhibitors

2. VISTA As Inhibitory & Costimulatory Checkpoint

2.1 VISTA As Inhibitory Immune Checkpoint
2.2 VISTA As Costimulatory Checkpoint
2.3 VISTA Inhibition v/s Conventional Immune Checkpoint Inhibitors

3. Significance Of VISTA In Disease Progressiopn & Cure

3.1 Role Of VlSTA In Facilitating Cancer Progression
3.2 VISTA As Potential Cancer Biomarker
3.3 VISTA As Therapeutic Target In Autoimmune Diseases

4. Global VISTA Inhibitors Market & Clinical Development Outlook

4.1 Current Scenario
4.2 Future Opportunities

5. VISTA Targeted Therapies Trends & Clinical Innovation By Indication

5.1 Solid Cancers
5.2 Hematological Cancers
5.3 Autoimmune & Inflammatory Disorders

6. VISTA Targeted Therapies Trends & Clinical Innovation By Region

6.1 US
6.2 Europe
6.3 India
6.4 Australia

7. Global VISTA Inhibitors Clinical Trials Overview

7.1 By Country
7.2 By Indication
7.3 By Organization
7.4 By Phase

8. Global VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase

8.1 Preclinical
8.2 Phase I
8.3 Phase I/II
8.4 Phase III

9. Global VISTA Inhibitors Market Dynamics

9.1 Market Drivers
9.2 Market Challenges

10. Competitive Landscape

10.1 Aurigene Discovery Technologies
10.2 Curis
10.3 Hummingbird Bioscience
10.4 Kineta
10.5 PharmAbcine
10.6 Sensei Biotherapeutics

简介目录图表

List of Figures

Figure 1-1: VISTA Protein - Structure
Figure 1-2: VISTA - Binding Partners
Figure 1-3: VISTA Inhibition - Basic Mechanism
Figure 2-1: VISTA - Role In Cancer Immunotherapy
Figure 2-2: VISTA - Role In Autoimmune Diseases
Figure 2-3: VISTA Inhibition - Edge Over Conventional Checkpoint Inhibition
Figure 3-1: VISTA Interaction With Immune Cells
Figure 3-2: VISTA - Mechanisms Of Immune Suppression
Figure 3-3: Dual Role Of VISTA In Cancer
Figure 3-4: VISTA As Predictive Biomarker
Figure 3-5: Autoimmune Diseases - VISTA Agonism
Figure 4-1: Future Market Opportunities
Figure 5-1: Solid Tumors - VISTA Role In Tumor Immune Evasion
Figure 5-2: SNS-101-2-1 Phase 1/2 (NCT05864144) Study - Initiation & Completion Year
Figure 5-3: HMBD-002-V4C26-01 Phase 1/2 (NCT05082610) Study - Initiation & Completion Year
Figure 5-4: Hematological Cancers - Mechanisms Of Immune Evasion By VISTA
Figure 5-5: Autoimmune & Inflammatory Disorders - VISTA As Ligand On APCs
Figure 5-6: Autoimmune & Inflammatory Disorders - VISTA As Receptor On T Cells
Figure 5-7: Kings College London & Dartmouth College VISTA Patent - Grant & Expiration Year
Figure 6-1: MarkV-01/KEYNOTE-E80 Phase 1 (NCT05957081) Study - Initiation & Completion Year
Figure 7-1: Global - Number Of VISTA Inhibitors In Clinical Trials By Country, 2025
Figure 7-2: Global - Number Of VISTA Inhibitors In Clinical Trials By Indication, 2025
Figure 7-3: Global - Number Of VISTA Inhibitors In Clinical Trials By Organization, 2025
Figure 7-4: Global - Number Of VISTA Inhibitors In Clinical Trials By Phase, 2025
Figure 9-1: Market Drivers & Opportunities
Figure 9-2: Market Challenges & Restraints

List of Tables

Table 5-1: VISTA - Role In Autoimmune & Inflammatory Disorders
Table 6-1: US - Ongoing Clinical Trials for VISTA Inhibitors

02-2729-4219

+886-2-2729-4219

License/价格

VISTA抑制剂的全球市场:临床试验，医药品开发机会，专利的洞察(2025年)

Global VISTA Inhibitor Clinical Trials, Drug Development Opportunities & Patent Insight 2025

目录

第1章新免疫查核点的VISTA

第2章阻碍及共刺激查核点的VISTA

第3章疾病的进展和治癒的VISTA的重要性

第4章全球VISTA抑制剂市场与临床开发的展望

第5章 VISTA标靶治疗趋势与各适应症临床革新

第6章 VISTA标靶治疗的地区趋势与临床革新

第7章 VISTA抑制剂的世界临床试验概要

第8章企业，国家，适应症，各期的VISTA抑制剂的临床试验相关全球洞察

第9章全球VISTA抑制剂市场动态

第10章竞争情形